DETECTION OF SARS-CoV-2 ANTIBODIES

PerkinElmer Assays for Detection of SARS-CoV-2

Immunoassays detect antibodies to SARS-CoV-2 instead of identifying the live virus. According to the FDA, antibodies to SARS-CoV-2 develop approximately one to three weeks after infection and persist for a long period of time. Therefore, antibody determination is not a suitable measure to identify people who are infectious. They are not suitable to determine the difference between a sample from a person with an active infection who can spread the disease and a sample from a person who has recovered from the infection. However, they can be quite valuable as a tool for disease surveillance and investigational purposes.

PerkinElmer offers a number of different types of SARS-CoV-2 immunoassays with varied samples types, throughputs, run times, and targets. The table below will help you decide which solution best fits your needs.

SuperFlex

Direct chemiluminescence

Coviscreen

Immuno-chromatography

GSP®/DELFIA®

Time-resolved fluorescence

EUROIMMUN*

Enzyme-linked immunosorbent assay

Run Time 15 minutes
(12 samples)
 20 minutes
(1 sample)
< 2 hours
(96 samples)
2.5 hours
Throughput
(24 hours)
Automated ~ 1,152 Manual – Variable Automated ~ 5,000 Automated ~ 2,100
Manual – Variable
Ab target  IgG (S1) IgA+IgM+IgG (S1) IgG (S1) IgA (S1)
IgM (NCP)
IgG (S1, NCP)
Sample type Serum, Plasma, Whole Blood Serum, Plasma, Fingerpick Whole Blood Serum, Dried Blood Spot Serum, Dried Blood Spot for IgG
SARS-CoV-2 Antibody Assays

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

* For emergency use authorization only. Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.